ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 380,74
0,92%
Dow Jones
42 742,24
0,40%
DAX
19 909,14
-0,25%
Brent Oil
74,565
0,63%
Bitcoin
95 248,32
2,79%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Sagiment Biosciences Inc (SGMT) Cours

Sagiment Biosciences Inc

Sagiment Biosciences Inc (SGMT)

NASDAQ
4,66
-0,06
( -1,27% )
Mis à jour : 16:07:41
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
4,66
Prix Achat
4,65
Prix Vente
4,71
Volume échangé
75 483
4,66 Fourchette du Jour 4,82
2,39 Plage de 52 semaines 20,71
Cap du marché
142,945M
Clôture Veille
4,72
Ouverture
4,72
Dernière Transaction
100
@
4.66
Dernière heure de transaction
16:07:41
Volume financier
US$ 356 913
VWAP
4,7284
Volume moyen (3 m)
721 519
Actions en circulation
30 674 855
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-5,19
Bénéfice par action (BPA)
-0,91
Chiffre d'affairess
2M
Bénéfice net
-27,88M

À propos de Sagiment Biosciences Inc

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.sagimet.com
Siège social
Camden, Delaware, USA
Fondé
-
Sagiment Biosciences Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker SGMT. Le dernier cours de clôture d'Sagiment Biosciences était de US$4,72. Au cours de la dernière année, les actions de Sagiment Biosciences ont été négociées dans une fourchette de prix de US$ 2,39 à US$ 20,71.

Sagiment Biosciences compte actuellement 30 674 855 actions en circulation. La capitalisation boursière d'Sagiment Biosciences est de US$144,79 million. Sagiment Biosciences a un ratio cours/bénéfice (ratio PE) de -5.19.

SGMT Dernières nouvelles

Plus de nouvelles

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 Novembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Novembre 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

27 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

16 Août 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

15 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Août 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Août 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.32-6.425702811244.985.144.622480754.91922648CS
4-0.67-12.57035647285.336.444.35577514445.34035316CS
120.4911.75059952044.176.443.687215195.30649086CS
261.2637.05882352943.46.442.399630953.96808882CS
52-0.69-12.89719626175.3520.712.3910439067.02443205CS
156-10.84-69.93548387115.520.712.137549627.13798931CS
260-10.84-69.93548387115.520.712.137549627.13798931CS

SGMT - Frequently Asked Questions (FAQ)

What is the current Sagiment Biosciences share price?
The current share price of Sagiment Biosciences is US$ 4,66
How many Sagiment Biosciences shares are in issue?
Sagiment Biosciences has 30 674 855 shares in issue
What is the market cap of Sagiment Biosciences?
The market capitalisation of Sagiment Biosciences is USD 144,79M
What is the 1 year trading range for Sagiment Biosciences share price?
Sagiment Biosciences has traded in the range of US$ 2,39 to US$ 20,71 during the past year
What is the PE ratio of Sagiment Biosciences?
The price to earnings ratio of Sagiment Biosciences is -5,19
What is the cash to sales ratio of Sagiment Biosciences?
The cash to sales ratio of Sagiment Biosciences is 72,39
What is the reporting currency for Sagiment Biosciences?
Sagiment Biosciences reports financial results in USD
What is the latest annual turnover for Sagiment Biosciences?
The latest annual turnover of Sagiment Biosciences is USD 2M
What is the latest annual profit for Sagiment Biosciences?
The latest annual profit of Sagiment Biosciences is USD -27,88M
What is the registered address of Sagiment Biosciences?
The registered address for Sagiment Biosciences is 2140 SOUTH DUPONT HIGHWAY, CAMDEN, DELAWARE, 19934
What is the Sagiment Biosciences website address?
The website address for Sagiment Biosciences is www.sagimet.com
Which industry sector does Sagiment Biosciences operate in?
Sagiment Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
APMAptorum Group Ltd
US$ 5,08
(274,91%)
56,41M
ONCOOnconetix Inc
US$ 1,40
(220,37%)
117,37M
BDMDBaird Medical Investment Holdings Ltd
US$ 3,2197
(206,64%)
3,71M
VRMEVerifyMe Inc
US$ 2,0008
(153,30%)
64,96M
SVMHSRIVARU Holding Ltd
US$ 0,0628
(88,02%)
211,15M
SGMOSangamo Therapeutics Inc
US$ 1,1879
(-49,24%)
10,64M
WATTEnergous Corporation
US$ 1,535
(-42,08%)
13,96M
COCPCocrystal Pharma Inc
US$ 1,92
(-40,92%)
216,65k
ARTWArts Way Manufacturing Co Inc
US$ 2,25
(-37,50%)
617,13k
GTIGraphjet Technology
US$ 0,9373
(-28,99%)
5,5M
EYENEyenovia Inc
US$ 0,1782
(57,28%)
225,54M
SVMHSRIVARU Holding Ltd
US$ 0,0628
(88,02%)
211,15M
CRKNCrown Electrokinetics Corporation
US$ 0,1961
(41,38%)
202,39M
XTIAXTI Aerospace Inc
US$ 0,0426
(7,85%)
154,33M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,1961
(58,66%)
134,97M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
SGMT
Sagiment Biosciences
LSE
0ND9
H2 Core
AMEX
IHE
iShares US Pharmaceuticals
NYSE
SAN
Banco Santander
FX
GBPPKR
Sterling vs PKR
BIT
P1ELS2
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés